Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Prostatic Neoplasms 4Oligodendroglioma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1

Interventions

Gemcitabine 3Cisplatin 3temsirolimus 1pembrolizumab 1enfortumab vedotin 1Magnetic Resonance Spectroscopy 1Carboplatin 1ALT-801 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Urethral Neoplasms × temsirolimus × Clear all
NCT01090466 2018-02-06

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Cardiff University

Phase 1/2 Completed
15 enrolled
Genitourinary

Urinary Bladder Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡